Recombinant Human Transmembrane gamma-carboxyglutamic acid protein 2 (PRRG2)

What is the molecular structure of PRRG2?

PRRG2 is a single-pass integral membrane protein of approximately 200 amino acids in length. It belongs to the family of transmembrane gamma-carboxyglutamic acid (Gla) proteins characterized by an extracellular N-terminal domain of approximately 45 amino acids rich in Gla residues. The protein contains a predicted propeptide and Gla domain, a single-pass transmembrane segment, and tandem Pro/Leu-Pro-Xaa-Tyr (PY) motifs near its C terminus. The molecular structure includes an extracellular Gla domain with potential Gla residues, followed by a membrane-spanning hydrophobic region and a cytoplasmic carboxyl terminal region containing PPXY motifs . The recombinant human PRRG2 protein fragment (1-86 aa range) has the following amino acid sequence: MRGHPSLLLLYMALTTSLDTSPSEEETDQEVFLGPPEAQSFLSSHTRIPRNHWDLELLPTPGNLERECLEERCSWEEAREYFEDNTL .

How does PRRG2 undergo post-translational modification?

PRRG2 undergoes γ-glutamyl carboxylation in a process that is dependent on:

• The presence of a proteolytically cleavable propeptide

• Vitamin K as a cofactor

• The enzymatic action of γ-glutamyl carboxylase that occurs within the lumen of the endoplasmic reticulum (ER)

This carboxylation process is sensitive to warfarin, a vitamin K antagonist widely used as an antithrombotic agent. When expressed at physiologically relevant levels, the majority of PRRG2 is present in the γ-glutamyl carboxylated, propeptide-cleaved (mature) form. Researchers can study this modification by treating cells expressing PRRG2 with vitamin K (20 μg/ml) or warfarin (300 μg/ml) and analyzing the modifications through immunoprecipitation with Gla-specific antibodies followed by immunoblotting .

What are the key functional domains of PRRG2 and their significance?

PRRG2 contains several key functional domains that contribute to its biological activities:

These domains enable PRRG2 to function as a potential cell-surface receptor with the ability to transduce signals across the plasma membrane .

What is the subcellular localization of PRRG2?

PRRG2 is predominantly located on the cell surface with its Gla domain exposed extracellularly. This has been demonstrated through Western blotting and flow cytometry analyses. The protein adopts a transmembrane orientation where the N-terminal Gla domain is exposed to the extracellular environment, while the C-terminal region containing the PPXY motifs extends into the cytoplasm. This orientation allows the protein to potentially function as a cell surface receptor, transmitting signals from the extracellular environment to the cytoplasm. During its biosynthesis, the protein's N-terminal domain is exposed to the γ-glutamyl carboxylase within the lumen of the endoplasmic reticulum, facilitating the post-translational carboxylation reaction .

What is the tissue distribution pattern of PRRG2?

PRRG2 exhibits a broad and variable distribution in both fetal and adult human tissues. Quantitative real-time PCR analysis has been used to assess PRRG2 expression levels across different tissues, normalizing results against POLR2A as a reference gene. While specific expression levels vary between tissues, PRRG2 is not restricted to any particular organ system, suggesting it may have diverse physiological functions depending on the tissue context. This broad distribution pattern distinguishes PRRG proteins from other vitamin K-dependent proteins that are primarily expressed in the liver and bone .

How can researchers accurately quantify PRRG2 expression in different tissues?

To accurately quantify PRRG2 expression in different tissues, researchers can employ the following methodology:

• RNA purification from tissues of interest

• TaqMan® one-step RT-PCR master mix for quantitative real-time PCR

• Use of specific TaqMan gene expression assays (Assay ID: Hs00168745_m1 for human PRRG2)

• Normalization of results against a housekeeping gene such as POLR2A (Assay ID: Hs00172187_m1)

• Relative quantification using the 2^(-ΔΔCt) method

For tissue samples with low expression levels, researchers should consider enrichment methods or digital PCR for more sensitive detection. Additionally, researchers can validate mRNA expression findings at the protein level using Western blotting or immunohistochemistry with validated antibodies specific to PRRG2 .

What is known about PRRG2 expression in kidney renal clear cell carcinoma (KIRC)?

Studies have demonstrated a significant decrease in PRRG2 expression in kidney renal clear cell carcinoma (KIRC) compared to normal kidney tissues. This downregulation has been consistently observed across multiple databases including TIMER, GEPIA, and UALCAN. Specifically:

• PRRG2 expression is significantly lower in KIRC tissues compared to adjacent normal tissues

• Reduced expression is observed across different patient demographics (both male and female patients)

• Low expression correlates with tumor grade, stage, and metastasis

• The downregulation is consistent across different age groups and ethnicities

These findings suggest that PRRG2 may play a tumor-suppressive role in KIRC, and its decreased expression could contribute to cancer development and progression .

How does PRRG2 expression correlate with clinical outcomes in KIRC patients?

PRRG2 expression levels have significant prognostic value in KIRC:

The prognostic significance of PRRG2 varies across different clinicopathological subgroups:

• Low PRRG2 expression correlates with poor OS in both male and female patients

• Low expression is associated with poor OS in patients of all age ranges, those in T3 stage, m0 stage, pathological stage IV, and histological grade G2

• Only KIRC patients aged ≤60 years showed correlation between low PRRG2 expression and progression-free survival

What methodological approaches can be used to study PRRG2's role in cancer?

To investigate PRRG2's role in cancer, researchers can employ multiple complementary approaches:

• Expression analysis:

  • TIMER database to analyze expression across 36 different carcinomas

  • GEPIA and UALCAN databases for comparative expression analysis between tumor and normal tissues

  • Direct analysis of TCGA data for paired samples (tumor vs. adjacent normal)

• Clinical correlation studies:

  • UALCAN online tool to assess expression in diverse patient groups based on clinical factors

  • Kaplan-Meier plotter to evaluate survival metrics (OS, DSS, PFI)

  • Stratification of patients by clinicopathological characteristics

• Functional genomics:

  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses

  • Gene Set Enrichment Analysis (GSEA)

  • Construction of gene-gene interaction networks using GeneMania

  • Protein-protein interaction network analysis using STRING database

• Immune infiltration analysis:

  • Tumor Immune Estimation Resource (TIMER) to assess correlation with immune cell infiltration

  • Analysis of association between PRRG2 expression and marker genes of immune cells

These methodologies provide a comprehensive approach to understanding PRRG2's role in cancer pathogenesis and its potential as a biomarker .

What are the key protein binding partners of PRRG2?

PRRG2 interacts with several proteins through its cytoplasmic PPXY motifs. Key binding partners include:

• Yes-associated protein (YAP): A WW domain-containing transcriptional coactivator involved in the Hippo signaling pathway

• NEDD4: An E3 ubiquitin-protein ligase

• MAGI family proteins: Including MAGI-1 (BAIAP1), MAGI-2 (AIP-1), and MAGI-3

• WWTR1 (TAZ): Another member of the Hippo pathway

• Other E3 ubiquitin-protein ligases: Including NEDD4L, ITCH, WWP1, and NEDL1

These interactions primarily occur through the binding of PRRG2's PPXY motifs to the WW domains of these partner proteins. Both PRRG2 PY motifs and both YAP WW domains are essential for complex formation, as are residues proximal to the core sequence of the first PY motif .

How can researchers experimentally investigate PRRG2 protein-protein interactions?

To investigate PRRG2 protein-protein interactions, researchers can employ several complementary experimental approaches:

• WW domain array screening:

  • Express the cytoplasmic domain of PRRG2 as a fusion protein

  • Screen against arrays containing various WW domains

  • Identify positive interactions for further validation

• GST pulldown assays:

  • Subclone the cytoplasmic domain of PRRG2 (e.g., amino acids 138-226) into expression vectors

  • Express as GST-tagged fusion proteins in bacterial or mammalian systems

  • Perform pulldown assays with candidate interacting proteins

  • Analyze by immunoblotting

• Co-immunoprecipitation:

  • Express full-length PRRG2 in appropriate cell lines (e.g., HEK293)

  • Immunoprecipitate with antibodies against PRRG2 or candidate interactors

  • Analyze precipitated complexes by Western blotting

• Yeast two-hybrid screening:

  • Use the C-terminal cytoplasmic region of PRRG2 as bait

  • Screen against a cDNA library of interest

  • Validate positive interactions with alternative methods

• Mutation analysis:

  • Generate PRRG2 variants with mutations in the PPXY motifs

  • Compare binding efficiency with wild-type protein

  • Identify critical residues for protein-protein interactions

These methodologies provide robust approaches to identify and characterize the molecular interactions of PRRG2, offering insights into its cellular functions .

What signaling pathways are associated with PRRG2 function?

PRRG2 has been implicated in several signaling pathways, as determined through Gene Set Enrichment Analysis (GSEA) and pathway enrichment studies:

• Immune response pathways:

  • Human immune response

  • Immune response-activating cell surface receptor signaling pathways

  • B cell receptor (BCR) signaling leading to secondary messenger generation

  • CD22-mediated BCR regulation

  • Immunoregulatory interactions between lymphoid and non-lymphoid cells

• Protein activation cascades:

  • Serine-type peptidase activities

  • Protein activation cascades

• Hippo signaling pathway:

  • Through interactions with YAP and TAZ

• Potential ubiquitin-mediated pathways:

  • Through interactions with E3 ubiquitin ligases like NEDD4

These pathways suggest that PRRG2 may function as a cell surface receptor involved in immune regulation and signal transduction. The involvement in multiple pathways aligns with its broad tissue distribution and suggests context-dependent functions .

How does PRRG2 potentially impact immune infiltration in cancers?

PRRG2 expression significantly correlates with immune cell infiltration in kidney renal clear cell carcinoma (KIRC), suggesting a potential role in tumor immunology:

• Correlation with immune cell populations:

  • PRRG2 expression is significantly associated with infiltration of B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages, and dendritic cells in KIRC

  • This correlation has been established using the Tumor Immune Estimation Resource (TIMER)

• Association with immune marker genes:

  • PRRG2 expression correlates with expression of multiple gene marker sets of immune cells

  • These correlations suggest functional relationships between PRRG2 and various immune cell types

• Enrichment in immune-related pathways:

  • Gene Set Enrichment Analysis (GSEA) shows significant enrichment of PRRG2 in immune-related activities

  • These include BCR signaling, CD22-mediated BCR regulation, and immunoregulatory interactions

• Potential mechanisms:

  • PRRG2 may regulate immune cell recruitment and activation

  • It could influence the tumor microenvironment through cytokine signaling

  • Its decreased expression in KIRC might contribute to immune evasion

Understanding these relationships could provide insights into how PRRG2 influences cancer progression and patient outcomes, potentially through modulation of the tumor immune microenvironment .

What are the effects of warfarin on PRRG2 function and potential clinical implications?

Warfarin, a vitamin K antagonist widely used as an antithrombotic agent, significantly impacts PRRG2 function through inhibition of its post-translational modification:

• Molecular effects:

  • Inhibits γ-glutamyl carboxylation of PRRG2

  • Prevents formation of mature, functional PRRG2 protein

  • May impair PRRG2-mediated signal transduction pathways

• Experimental evidence:

  • Studies show that warfarin treatment (300 μg/ml) inhibits the γ-carboxylation of PRRG2

  • This inhibition is detectable by reduced recognition of PRRG2 by Gla-specific antibodies

• Potential clinical implications:

  • Impairment of PRRG2 function may be an unintended consequence of warfarin therapy

  • Could contribute to some warfarin side effects beyond coagulation

  • May have relevance for fetal development during pregnancy due to PRRG2's broad expression in fetal tissues

• Research considerations:

  • Understanding warfarin's effects on PRRG2 may help explain teratogenic consequences of in utero warfarin exposure

  • Could provide insights into novel physiological functions of vitamin K beyond blood coagulation and bone development

These findings highlight the importance of considering PRRG2 inhibition as a potential off-target effect of warfarin therapy, particularly in contexts where PRRG2 signaling may be clinically significant .

How does PRRG2 compare with other members of the transmembrane Gla protein family?

PRRG2 is part of a family of transmembrane Gla proteins that includes PRGP1/PRRG1, PRRG2, TMG3/PRRG3, and TMG4/PRRG4. These proteins share common features but also display distinct characteristics:

The family can be divided into two subclasses based on gene organization and amino acid sequence:

• PRGP1/TMG3 subclass

• PRRG2/TMG4 subclass

This classification reflects evolutionary relationships and potentially functional similarities within each subclass. Despite shared structural features, the proteins may have distinct tissue-specific functions based on their variable expression patterns .

What expression systems are optimal for recombinant PRRG2 production?

For successful recombinant PRRG2 production, researchers should consider the following expression systems based on experimental goals:

• Mammalian expression systems (recommended):

  • HEK293 cells are widely used for PRRG2 expression

  • Advantages: Proper post-translational modifications (especially γ-carboxylation), appropriate folding, and physiological processing

  • Suitable vectors: pcDNA3.1/V5-His for cellular localization studies, Gateway pDEST27 for mammalian expression of GST-tagged proteins

  • Essential supplements: Vitamin K (20 μg/ml) should be added to ensure proper γ-carboxylation

• Bacterial expression systems:

  • Suitable for non-modified cytoplasmic domains only

  • Gateway pDEST15 vector can be used for bacterial expression of GST-tagged PRRG2 cytoplasmic domain

  • Not suitable for full-length protein or studies requiring γ-carboxylation

• Commercial sources:

  • Recombinant Human PRRG2 protein (Fc Chimera) expressed in HEK293 cells is commercially available

  • Contains amino acids 1-86 with >90% purity and <1 EU/μg endotoxin level

The choice of expression system should be guided by the specific research question, with mammalian systems being essential for studies involving post-translational modifications or membrane localization .

What methodological approaches can be used to study PRRG2's role in signal transduction?

To investigate PRRG2's role in signal transduction, researchers can employ multiple experimental approaches:

• Domain-specific functional analysis:

  • Generate constructs with mutations in key domains (PPXY motifs, Gla domain)

  • Assess effects on downstream signaling pathways

  • Use deletion mutants to identify minimal functional domains

• Protein-protein interaction dynamics:

  • Real-time binding assays to measure interaction kinetics

  • FRET/BRET studies to monitor protein interactions in living cells

  • Proximity ligation assays to visualize endogenous protein complexes

• Signaling pathway activation:

  • Monitor YAP/TAZ nuclear translocation upon PRRG2 activation/inhibition

  • Assess transcriptional regulation of YAP/TAZ target genes

  • Measure activation of key signaling intermediates by phospho-specific antibodies

• Vitamin K dependency studies:

  • Compare signaling outcomes in vitamin K-supplemented vs. warfarin-treated conditions

  • Correlate γ-carboxylation status with signaling efficiency

  • Use Gla-specific antibodies to differentiate carboxylated from non-carboxylated forms

• Gene expression manipulation:

  • siRNA/shRNA knockdown of PRRG2 to assess loss-of-function effects

  • CRISPR/Cas9 genome editing to generate cellular models with PRRG2 modifications

  • Overexpression studies with wild-type and mutant PRRG2 variants

These approaches provide complementary information about how PRRG2 participates in cellular signaling networks and how its function is regulated by post-translational modifications .

How can researchers resolve contradictory findings in PRRG2 expression data across different databases?

When encountering contradictory PRRG2 expression data across different databases, researchers should implement the following methodological approach:

• Data source evaluation:

  • Assess sample size and statistical power of each dataset

  • Determine normalization methods used in each database

  • Consider platform-specific biases (microarray vs. RNA-seq)

  • Evaluate whether paired or unpaired samples were used

• Direct validation approaches:

  • Perform quantitative RT-PCR on independent sample cohorts

  • Use multiple primer sets targeting different regions of the PRRG2 transcript

  • Validate at protein level using Western blotting or immunohistochemistry

  • Compare with in situ hybridization to detect tissue-specific expression

• Meta-analysis strategies:

  • Systematically combine data from multiple sources using appropriate statistical methods

  • Weight studies based on sample size and quality metrics

  • Perform subgroup analyses based on patient characteristics

  • Use forest plots to visualize consistency across studies

• Consideration of biological variables:

  • Stratify data by relevant clinical parameters (age, sex, disease stage)

  • Account for potential splice variants or isoforms

  • Consider cell type heterogeneity within tissue samples

  • Evaluate effects of treatments or comorbidities

• Technical verification:

  • Cross-reference with proteomic data where available

  • Examine single-cell RNA-seq data to resolve cell type-specific expression

  • Consider epigenetic regulation that might affect expression in different contexts

This systematic approach helps resolve contradictions and provides a more accurate understanding of PRRG2 expression patterns across different physiological and pathological conditions .